MNOV today
$1.41+$0.01 (+0.71%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourSymmetric Triangle
1 hourLeaning Bullish
15 minBullish
5 minConsolidating
Daily trend turns up above $2.55
Key levels
Resistance$1.59
Resistance$1.43
Support$1.32
Support$1.20
Latest news & SEC filings
ProductMediciNova shares Phase 2 topline data for MN-001 in NAFLD and high blood fats
All MNOV news →About MediciNova
MediciNova is a biopharmaceutical company that develops drug candidates for illnesses where current treatment options are limited, aiming primarily at the U.S. market. Its two main programs are MN-166 (ibudilast), being studied for neurological conditions including progressive multiple sclerosis, ALS, degenerative cervical myelopathy, and glioblastoma, and MN-001 (tipelukast), being studied for liver and metabolic conditions such as NAFLD and elevated triglycerides. The company has no approved products and runs clinical trials, some through academic and government partnerships, at sites across North America and Europe.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
MEDICINOVA INC (MNOV)
What Is the Price Target for MNOV?
SEPT Low Target
$6.00
SEPT Mid Target
$6.00
SEPT High Target
$6.00
Analyst Consensus
$6.00
Is MNOV a Buy or Sell Right Now?
Thesis
- •Revenue growing -59.0% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 1 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MNOV.
Start Free Trial →Is MNOV Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$4.98
27
Moat Score
NONE
2/9
Piotroski Score
-3.4
Altman Z-Score
What Is Smart Money Doing with MNOV?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd. | other | Sale | 640,000 | $1.7M | Sep 25, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MNOV Growth Story
Revenue YoY
-59.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-4.35%
FCF Growth YoY
7.8%
Revenue Trend
ACCELERATING
Dark Pool Trades for MNOV
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MNOV, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:29:18 | $1.41 | 1,000 | $$1K | BUY |
| 17:18:12 | $1.40 | 1,553 | $$2K | SELL |
| 14:47:55 | $1.41 | 2,000 | $$3K | MIDPOINT |
| 18:57:10 | $1.41 | 2,000 | $$3K | MIDPOINT |
| 16:09:07 | $1.41 | 1,400 | $$2K | BUY |
5 dark pool trades shown · $$11K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MEDICINOVA INC (MNOV) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MNOV — frequently asked questions
What is MNOV stock price today?
MEDICINOVA INC (MNOV) is at $1.41, up 0.71% (+$0.01) at the Nov 13, 2026 close.
Why is MNOV stock moving today?
Latest MNOV news — Oct 12, 2026: MediciNova shares Phase 2 topline data for MN-001 in NAFLD and high blood fats
What is the MNOV price target?
The average analyst price target for MNOV is $6.00, ranging from $6 to $6, based on 2 analysts. Latest: MediciNova upgrade on Sep 17, 2026.
What do analysts rate MNOV?
Analyst ratings for MNOV: 1 Buy, 1 Hold, 0 Sell — consensus Hold.
Did MNOV beat earnings?
MNOV last reported on Aug 13, 2026: EPS -$0.05 vs -$0.06 expected — a beat of 21.0%.
Does MNOV pay a dividend?
MNOV does not currently pay a dividend.
What are MNOV support and resistance levels?
Support: $1.32, $1.20. Resistance: $1.43, $1.59, $1.83.
What are insiders doing with MNOV?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on MNOV?
Oct 12, 2026: MediciNova shares Phase 2 topline data for MN-001 in NAFLD and high blood fats